Remimazolam: target-controlled infusion versus manual infusion during cerebrovascular bypass
Official title: Comparison of Remimazolam Consumption According to Administration Method in Patients Undergoing Cerebrovascular Bypass Surgery: A Prospective Randomized Trial
Run by Seoul National University Hospital · NCT07377695 · Data updated 2026-11-12
This trial will test whether target-controlled infusion uses less remimazolam than manual infusion in adults undergoing cerebrovascular bypass surgery for moyamoya disease.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 19 Years and up |
| Sex | All |
| Enrollment | 58 (estimated) |
| Sponsor | Seoul National University Hospital Academic / other |
| Locations | 1 site (Seongnam-si, Gyeonggi-do) |
| Status | Recruiting |
| Started | February 4, 2026 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2030 |
| Registry record updated | April 23, 2026 |
| Trial ID | NCT07377695 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 19 or older with moyamoya disease scheduled for cerebrovascular bypass under general anesthesia, ASA 1–3, who can provide informed consent and meet safety criteria.
✕Probably not a fit
Patients who are ASA 4, have extreme BMI (<18.5 or ≥35 kg/m2), benzodiazepine allergy, acute narrow-angle glaucoma, severe respiratory disorders (including untreated sleep apnea), alcohol or drug dependency, or lactose/dextran hypersensitivity are excluded and unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective randomized controlled trial compares total remimazolam consumption between target-controlled infusion (TCI) and manual infusion in patients undergoing cerebrovascular bypass surgery. Adult patients (aged ≥19) with ASA physical status 1–3 who provide informed consent will be randomized to receive remimazolam by TCI or by manual infusion during general anesthesia. The primary outcome is total remimazolam use during the procedure, with intraoperative hemodynamic and safety data collected as secondary measures. The study is conducted at Seoul National University Bundang Hospital.
Why it matters
Potential benefit: If successful, the trial could identify a dosing method that reduces remimazolam use and improves dosing precision and perioperative stability.
How similar studies have gone: While TCI has improved dosing precision for other intravenous anesthetics, applying TCI specifically to remimazolam in cerebrovascular bypass is relatively novel with limited published evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients scheduled to undergo cerebrovascular bypass surgery under general anesthesia. * American Society of Anesthesiologists (ASA) Physical Status 1, 2, or 3 * Adults aged 19 years or older * Patients who have provided prior written informed consent to participate in the study Exclusion Criteria: * Patients who do not consent to participate in the research * Patients classified as ASA Physical Status 4 * Patients with a BMI ≤18.5 kg/m2 or 35.0 ≥ kg/m2 * History of allergy to benzodiazepine-class medications * Patients with acute narrow-angle glaucoma * Patients in a state of shock or coma * Acute alcohol intoxication with suppressed vital signs , or patients with alcohol or drug dependency * Presence of Sleep Apnea Syndrome or severe/acute respiratory failure * Patients with lactose intolerance or hypersensitivity to Dextran 40
Where it's running
-
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea Recruiting
Study contacts
- Study coordinator: Chang-Hoon Koo
- Email: vollock9@gmail.com
- Phone: +82317877512
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Risk prediction for stroke and cognitive decline in Moyamoya disease and Moyamoya syndrome
A large multicenter study tests whether combining clinical data, imaging, lab and genetic information can predict who will have stroke or cognitive decline among people with Moyamoya.
-
5T MRI and Metabolomics to Predict Hemorrhage Risk in Moyamoya Disease
This study tests whether advanced 5T MRI imaging and metabolomics can help predict which moyamoya patients are at higher risk of intracranial hemorrhage.
-
XR-assisted CT-guided localization for EC-IC bypass in Moyamoya and chronic cerebral ischemia
The study tests whether a metaverse-based surgical simulation with extended reality helps localize vessels during EC-IC bypass for moyamoya disease or chronic cerebral ischemia.
-
Family screening and early detection for moyamoya disease
This project will try to find biological signs and 5T high-resolution MRI features that could detect moyamoya earlier in people with the disease, their first-degree relatives, and people without a family history.
-
Cardiac index–guided blood flow management during pediatric Moyamoya EDAS surgery
This study will test whether using each child's cardiac index to guide fluids and hemodynamic care during EDAS lowers postoperative transient ischemic episodes in children with Moyamoya disease.
-
Combined cognitive and motor training for people with stroke or Moyamoya disease
This trial will test whether combined cognitive-motor training helps people with post-stroke cognitive impairment or Moyamoya disease improve their thinking and movement.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.